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Abstract
Phase I dose-finding studies aim at identifying the maximal toler-
ated dose (MTD). It is not uncommon that several dose-finding studies
are conducted, although often with some variation in the administration
mode or dose panel. For instance, sorafenib (BAY 43-900) was used as
monotherapy in at least 29 phase I trials according to a recent search in
clinicaltrials.gov. Since the toxicity may not be directly related to
the specific indication, synthesizing the information from several studies
might be worthwhile. However, this is rarely done in practice and only
a fixed-effect meta-analysis framework was proposed to date. We devel-
oped a Bayesian random-effects meta-analysis methodology to pool several
phase I trials and suggest the MTD. A curve free hierarchical model on
the logistic scale with random effects, accounting for between-trial hetero-
geneity, is used to model the probability of toxicity across the investigated
doses. An Ornstein-Uhlenbeck Gaussian process is adopted for the ran-
dom effects structure. Prior distributions for the curve free model are
based on a latent Gamma process. An extensive simulation study showed
good performance of the proposed method also under model deviations.
Sharing information between phase I studies can improve the precision of
MTD selection, at least when the number of trials is reasonably large.
1 Introduction
Phase I dose-finding studies are carried out during early stages of the clinical
development, and aim at estimating the maximum tolerated dose (MTD) of a
drug or a combination of molecules. The MTD is defined with reference to the
occurrence of treatment-related adverse events, so-called dose-limiting toxicities
(DLTs). The MTD then is reached once the rate of DLTs exceeds an acceptable
level. Phase I studies are usually done on small numbers of healthy volunteers,
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except in oncology, where, due to the potentially high toxicity of drugs, phase I
trials are commonly performed on patients (Chevret, 2006).
In oncology, identifying the correct or reasonable dose or set of doses is a
crucial objective in the drug development process: selecting too high a dose
means exposing patients to an unacceptable toxicity profile, while selecting a
dose of too low toxicity increases the likelihood that the treatment provides in-
sufficient efficacy (Bretz et al., 2005). The dose escalation paradigm in phase I
(or I/II) trials thus generally aims to avoid recommending too toxic doses of
an agent while maintaining an acceptable toxicity. Due to limited sample sizes,
conventional statistical methods are often inaccurate, so that adaptive sequen-
tial analyses have been proposed, as these can potentially find the MTD sooner
and limit the number of exposed subjects (Le Tourneau et al., 2009; Neuen-
schwander et al., 2015).
When combining data across trials, two sources of potential heterogeneity
need to be considered. Firstly, these are differences in the outcomes of the con-
trol groups. In the context of dose-escalation studies, there might be differences
in the (true) toxicity probabilities due to variations in e.g. the study populations
or in the definition and assessment of toxicities. Secondly, the (true) treatment
effects, even if defined on a relative scale, might vary across trials. In standard
meta-analysis models, the former is addressed by stratification for study. In
so-called random-effects meta-analyses, the latter is addressed by inclusion of
random study-by-treatment interactions. In fixed-effect or common-effect meta-
analysis, a homogeneous treatment effect across trials is assumed. For a recent
discussion of the various statistical models we refer here to Jackson et al. (2018).
As evidenced by large-scale empirical investigations, some level of between-study
heterogeneity is not unlikely to occur (Turner et al., 2012). However, estimation
of the corresponding variance component and accounting appropriately for the
uncertainty in estimation in inference of relevant model parameters can be chal-
lenging, if the number of studies included in the meta-analysis is small (Friede
et al., 2017). In the context of meta-analyses of dose-escalation trials, we are
still lacking an understanding as well as empirical evidence how the various
forms of between-trial heterogeneity can be appropriately accounted for.
Zohar et al. (2011) proposed a meta-analysis approach for phase I clinical
trials in oncology. Phase I data were pooled while accounting for the sequential
nature of such trials in order to better estimate the overall MTD. However,
this method did not deal with several important characteristics associated with
phase I features. Firstly, data were pooled under several different administration
schedules, which may imply different toxicity profiles. Secondly, between-trial
heterogeneity was not taken into account, which may lead to inaccurate infer-
ence. Thirdly, as the pooled analysis was done retrospectively, it would have
been possible to take into account cycles, dose-modifications and long term
toxicities in order to better investigate the maximal dose regimen, but these
complexities were not addressed.
Thomas et al. (2014) reported the results of a meta-analysis based on dose-
response studies conducted by a large pharmaceutical company between 1998
and 2009. Data collection targeted efficacy endpoints, but safety data were not
extracted. The goal of this meta-analysis was to identify consistent quantitative
patterns in dose-response across different compounds and diseases. The meta-
analysis excluded oncology trials as these have different dosing objectives and
methods.
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In this manuscript, we develop a novel meta-analysis approach for phase I
clinical trials in oncology, which takes into account the different features de-
scribed above to better suit the requirements in estimating MTDs. We general-
ized the binomial-normal hierarchical model (BNHM), which is most commonly
used in the literature for meta-analysis of studies involving a single dose. In
the following section, two motivating examples are described. In Section 3, the
methodology is presented, along with prior distributions and different variations
of MTD definitions. In Section 4 we describe model variations and simulation
settings that we used to test the developed method and its sensitivity to vary-
ing circumstances. Finally, in Section 5, the new methodology is applied to the
motivating case studies and some limitations are discussed in Section 6.
2 Motivating examples
Some might believe that there are more phase III than phase I studies, and
so meta-analyses have largely focused on late-stage trials whereas opportuni-
ties in pooling phase I results have rarely been investigated. Furthermore, as
phase I studies usually have small sample sizes and are mostly algorithm-based
and only lately model based designs, methodologists have been less inclined
to embrace this issue. The first illustration concerns sorafenib (BAY 43-9006)
which is a kinase inhibitor approved for the treatment of advanced renal cell
carcinoma, hepatocellular carcinoma, and radioactive iodine resistant advanced
thyroid carcinoma. A search of the clinicaltrials.gov registry of clinical
trials at the end of June 2019 revealed that there are at least 833 studies using
sorafenib (at any recruitment stage and type of study) of which 248 studies were
labeled as “phase I” or “phase I/II” and 99 studies were labeled as “phase III”
or “phase II/III”. Of 248 phase I or phase I/II studies using sorafenib, 29 studies
used it in phase I as monotherapy (median sample size 22, range 2–158).
Today, the dose recommended by the European Medicines Agency (EMA) is
400 milligrams (mg) twice a day. Several phase I studies on sorafenib monother-
apy have been performed, and some of their results are summarized in Table 1.
Within these 14 trials, a total of 7 doses were tested, with most of these studies
targeting solid tumors or leukemia. DLT definitions were comparable, and most
of sorafenib schedules followed a 28-day cycle or similar.
Applying the common-effect approach proposed by Zohar et al. (2011) (in the
following referred to as the ZKO approach) to the sorafenib data (Table 1) and
using (0.05, 0.1, 0.2, 0.3, 0.45, 0.6, 0.65) as skeleton, that is the set of prior toxic-
ity probabilities for the doses (chosen in a reasonable shape according O’Quigley
and Zohar (2010) and Zohar et al. (2011)), the following estimated toxicity prob-
abilities are obtained: (0.012, 0.033, 0.093, 0.169, 0.308, 0.471, 0.53). Following
the ZKO approach, and assuming a toxicity threshold of 0.33, a dose of 600 mg
is estimated as MTD, while for a threshold of 0.2, the MTD is at 400 mg.
The second example concerns a combination therapy of irinotecan and S-
1 (S-1 refers to a combination of three pharmacological compounds, namely
tegafur, gimeracil, and oteracil potassium). Irinotecan is a topoisomerase 1
inhibitor. It has proven effective in combination with 5-fluorouracil (5-FU) but
was associated with many adverse events. This is why the association with S-1
instead of 5-FU was evaluated. In this case 11 studies were used (Table 2) in
which 10 doses were evaluated across all trials.
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Table 1: The results of 14 studies on sorafenib monotherapy. For each dose
considered in each trial, the numbers of patients experiencing dose-limiting tox-
icities events, and the total numbers of exposed patients are given.
Dose (mg)
Study 100 200 300 400 600 800 1000
Clark et al. (2005) 0/3 0/3 1/4 1/6 3/3
Awada et al. (2005) 0/4 0/3 1/5 1/10 7/12 1/3
Moore et al. (2005) 0/3 1/6 0/8 3/7
Strumberg et al. (2005) 1/5 1/6 0/15 4/14 2/7
Minami et al. (2008) 0/3 1/12 0/6 1/6
Miller et al. (2009) 8/34 6/20
Nabors et al. (2011) 0/3 1/6 0/3 1/5 3/3
Chen et al. (2014) 0/3 1/16
Jia et al. (2013) 3/4
Borthakur et al. (2011)-1 0/3 0/15 2/8
Borthakur et al. (2011)-2 0/3 1/7 2/6
Crump et al. (2010)-1 0/4 1/6 0/6 1/6
Crump et al. (2010)-2 0/3 1/6 0/3 2/6
Furuse et al. (2008) 0/12 1/14
Applying the ZKO method on the S-1 data (Table 2) and using (0.005,
0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.65, 0.70) as skeleton we obtain the following
estimated toxicity probabilities: (0.002, 0.026, 0.061, 0.141, 0.231,0.328, 0.43,
0.537, 0.592, 0.648). Assuming a toxicity threshold of 0.33, dose 90 mg/m2 is
estimated as MTD, while for a threshold of 0.2, the MTD is at 80 mg/m2.
In the two examples given above, not all trials shared the same doses, dose
ranges and sample size. The ZKO method was applied to estimate the overall
MTD. However, this is a simplistic way of pooling several adaptive sequential
phase I data sets and it can be seen as a fixed-effect meta-analysis method.
In the next section will be detailed our proposition taking into account these
specificities as well as inter and intra trial heterogeneity by developing a non-
parametric random-effects approach.
3 Methods
3.1 The dose-response model
In case of studies concerned with only a single dose, the binomial-normal hier-
archical model (BNHM), or an approximation, is most commonly used in the
literature (Jackson et al., 2018; Gu¨nhan et al., 2019). When moving to several
doses in the same study, we propose an extension of the BNHM that is adapted
to the dose-finding context, and that is able to also account for the ordering and
spacing among doses.
Let k ∈ {1, . . . ,K} be the study index, and i ∈ {1, . . . , I} be the dose
level index, where all doses di used in all trials are indexed in increasing order.
Especially with data combined from several studies, the dose steps, that is the
“spacing” between neighbouring doses di, may be rather different (see e.g. the
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Table 2: The results of 10 studies on combination therapy of irinotecan and S-1
(tegafur/gimeracil/oteracil). For each dose considered in each trial, the numbers
of patients experiencing dose-limiting toxicities events, and the total numbers
of exposed patients are given.
Dose (mg/m2)
Study 40 50 60 70 80 90 100 120 125 150
Ogata et al. (2009) 0/3 0/3 3/4
Inokuchi et al. (2006) 0/3 10/42 0/3 2/3
Goya et al. (2012) 0/3 0/3 3/5
Takiuchi et al. (2005) 1/6 0/3 0/4 3/6
Ishimoto et al. (2009) 0/3 0/3 0/3 2/4
Kusaba et al. (2010) 0/6 2/3
Nakafusa et al. (2008) 7/39 2/3
Shiozawa et al. (2009) 1/6 2/6 2/6 2/3
Yoda et al. (2011) 0/3 3/6
Komatsu et al. (2010) 1/9 1/9 0/3
irinotecan example in Table 2) and needs to be accounted for in the model. We
define δi,j as the metric, specifying the spatial proximity or distance between
doses. This may simply be defined as the plain difference (δi,j = di− dj).
However, in many cases it may make sense to rather consider relative differences
between dose levels on the logarithmic scale (δi,j = log(di)−log(dj) = log
(
di
dj
)
).
Another option may be to assume unit increments for neighbouring doses.
The number of patients in study k allocated to dose i is given by nik, while
Xik is the number of patients experiencing a DLT. We then propose the follow-
ing model:
Xik ∼ Binomial (nik, pik) (1)
logit(pik) =
∑
j≤i
µj + bik (2)
where pik is the probability of toxicity of dose i in the kth study. The proba-
bilities pik here are modelled on the logit-scale, with logit(x) = log
(
x
1−x
)
.
The fixed effects µ1 ∈ R and µi ∈ R+ (for i > 1) are common across all stud-
ies; the summation in (2) ensures non-decreasing overall mean probabilities of
toxicity with increasing dose. The random effects accounting for between-study
heterogeneity are represented by the (study-specific) vectors bk ∼ N(0,Σ),
where 0 represents the zero vector of dimension I and Σ = {σi,j}i,j=1,...,I the
variance-covariance matrix. In order to meaningfully generalize from the BNHM
for a single dose to a joint model for multiple doses, we specify the fixed and ran-
dom effects accounting for the corresponding dose levels (di) and their ordering
and proximity.
3.2 Gaussian process for the random effects
For the random effects, we specify a model that accounts for the position of
dose di on the dose continuum. We do not impose monotonicity here and we rely
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on a relatively simple class of Gaussian processes. Two interesting special cases
are encompassed by the model, namely independent and identical residuals at
all doses. In between these extremes, we utilize a stationary Ornstein-Uhlenbeck
process (OUP) with covariance
σ2i,j = σ
2
m exp
(
− |δi,j |`
)
(3)
where σ2m is the marginal variance, and ` > 0 is a smoothness parameter de-
termining how quickly the autocorrelation decays and residuals become less de-
pendent, depending on the spatial separation of doses. On small scales (relative
to `), the OUP behaves like a Wiener process (or Brownian motion); this nicely
corresponds with the notion that if we knew the residual at a certain dose, we
knew less about the neighbouring residual the further we moved away from that
dose, where increments behaved (approximately) additively, as for the fixed ef-
fects model introduced below. For the limiting cases of ` → 0 and ` → ∞ it
yields independent or identical residuals across doses, respectively (Uhlenbeck
and Ornstein, 1930; Doob, 1942). Prior distributions for the random effect’s
marginal variance σ2m and the OUP’s spatial scale ` need to be specified.
3.3 Gamma process for fixed effects prior distributions
The definition of the common effect via a sum of unknown increments in (2)
places the model into the class of stochastic processes, which are commonly used
as nonparametric models for unkown functions (Gelman et al., 2014, Ch. 21).
Therefore, the prior distributions on the unknown increments may be inspired
by a stochastic process. A natural and convenient class of models is defined via
infinitely divisible probability distributions (Steutel, 1979); that means that we
stay within the same distribution class for the increments (i.e., if we sum two
increments, the sum’s distribution again is within the same distribution class),
which results in an overall consistent model. Since in the present case we are
considering strictly positive increments for increasing doses, the Gamma process
is an obvious choice here (Lawless and Crowder, 2004).
The Gamma distribution is defined through two parameters, namely the
shape k > 0 and the scale θ > 0; its expectation then is kθ and the variance is
kθ2. Choosing the first dose (d1) as the reference dose, we can specify the prior
distributions as a Gamma process with
µ1 ∼ Normal(µ∗, σ∗), (4)
µi ∼ Gamma(k = δ∗i,i−1κ, θ) for i > 1, (5)
where δ∗i,i−1 is the dose increment from dose di−1 to di. To note, δ
∗ can be
equal to δ (used in the specification of the random effects), or it can use another
underlying metric. The parameter µ1 serves as an “intercept” term, and hyper-
parameters µ∗ and σ∗ then need to be specified with reference to the expected
toxicity at the reference dose. The Gamma process hyperparameters κ and θ
also need to be pre-specified. For a sensible choice, it is convenient to consider
their effect on the conditional distribution for a unit increment:
E[µi | δi,i−1=1] = κθ (6)
Var(µi | δi,i−1=1) = κθ2 (7)
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which suggests a re-parametrisation in terms of
slope a = κθ and (8)
coefficient of variation c =
1√
κ
. (9)
From this, we can see that for small c, the (logit-) toxicity behaves approximately
linear, while larger c values allow for departures from linearity. In the limiting
case of linearity, the model simplifies to a logistic model, which, in the special
case of dose increments defined on the logarithmic scale as suggested above,
again is a special case of the Emax model (Schwinghammer and Kroboth, 1988).
3.4 Prior effective sample sizes for fixed effects
In order to assess how informative certain choices of priors and hyperprior pa-
rameters for the fixed effect are, the notion of the effective sample size (ESS)
can be used for the final calibration of the prior distributions and/or hyperprior
parameters (Morita et al., 2008). In the present case, we suggest to compute the
approximate ESS as follows: (i) set the desired hyperparameters, (ii) simulate
from the resulting set of prior distributions, (iii) for each simulated vector value,
compute each pi using (2) without random effects, (iv) approximate each pi’s
distribution by a Beta(ai, bi), (v) compute the approximate ESS as
1
I
∑
i(ai+bi),
that is, the average of the ESS at each dose level.
3.5 MTD estimation
A range of rules have been proposed for estimating MTDs; several examples are
given in the following. The most popular way uses the posterior mean estimates
of the parameters in (2) and selects the MTD as the dose whose estimated DLT
probability is closest to the pre-specified target τ ∈ [0, 1] (Cheung, 2011). In
the meta-analysis context, we may focus on the overall fixed effect; inverting
from (2), we hence define
pii = logit
−1
(∑i
j=1 µj
)
(10)
where the inverse logit is given by logit−1(x) = (1 + exp(−x))−1. From this, we
may then derive
MTD = dj , where j = arg min
i
∣∣∣E[pii|y]− τ ∣∣∣, (11)
and where E[pii|y] denotes the posterior expectation of pii. The MTD is hence
defined as the dose with estimated overall mean response closest to the targeted
one. Alternatively, the posterior median may also be used instead of the mean
in (11) (Ursino et al., 2019).
In situations where investigators are particularly interested in overdose con-
trol, the classical escalation with overdose control (EWOC) principle may also
be applied, so that the MTD di is chosen as the largest dose satisfying
P
(
pii ≥ τ
∣∣ y) < τo, (12)
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Figure 1: Four different sets of probabilities p? used to set the fixed effects in
the data generation scenarios. a: p? =(0.15, 0.20, 0.33, 0,45, 0.55, 0.60, 0.65);
b: p? =(0.05, 0.10, 0.15, 0.33, 0.60, 0.70, 0.75); c: p? =(0.05, 0.07, 0.11, 0.20,
0.33, 0.45, 0.50); d: p? =(0.04, 0.05, 0.07, 0.12, 0.20, 0.33, 0.45).
that is, the dose whose posterior probability of exceeding the toxicity threshold τ
is less than a pre-specified threshold τo (Babb et al., 1998; Neuenschwander et al.,
2015). More complex rules, involving loss functions, such as the one applied for
the Bayesian Logistic Regression Model, can be also used (Neuenschwander
et al., 2008).
4 Simulations
We performed an extensive simulation study to evaluate the operating charac-
teristics of the proposed method. The aim was to compare the percentages of
correct MTD selection to the ones of the ZKO method in several scenarios. A
total of nine scenarios are proposed, with variations in the position of the MTD,
the heterogeneity structure and/or the design of the simulated trial. Details are
given in Section 4.1. Then we performed a sensitivity analysis aiming at checking
the impact of prior distribution/hyperparamter choices and of random-effects
model misspecification; details are shown in Sections 4.2 and 4.3.
4.1 Data generation scenarios
For each scenario, we simulated 1000 sets of completed trials that were sub-
sequently meta-analyzed. Motivated by the sorafenib example (see Table 1),
overall seven doses between d1 = 100 mg and d7 = 1000 mg were used. We
first set the true probabilities of toxicity of the scenario for each of the I = 7
doses involved, p? = (p?1, . . . , p
?
I). Four different sets of p
? were considered in
total; these are illustrated in Figure 1. Then, the between-trial heterogene-
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ity was added on the dose-transformed scale, in order to set the probabilities
of toxicity used to generate each single trial. However, since in our proposed
model we used the logit transformation, in order to not generate data from
the very same model, we opted for the probit function in data generation.
Therefore, for the kth trial of the jth meta-analysis run, we first generated
ptrkj = N (
(
Φ−1(p?1), . . . ,Φ
−1(p?I)
)
,Σ), where Φ(·) represents the cumulative dis-
tribution function of the standard normal distribution. Then, we computed the
probabilities as pkj =
(
Φ(ptr1,kj), . . . ,Φ(p
tr
I,kj)
)
. We used the same autocovari-
ance structure as in the estimation model (3) for all scenarios, allowing for a
different σm value, except for scenario 6, where Σ =
[
exp
(
− |δi,j |`
)
σiσj
]
, and
scenario 7, where Σ =
[
exp
(
− δ
2
i,j
2`2
)
σ2m
]
. For all scenarios, we set ` = 1 and
δi,j =
di−dj
I−1
∑I
n=1 di
, while δ∗i,j =
di−dj
100mg . This means that we used two related
scales for δ and δ∗, and that we utilise 100 mg as the measure unit for the fixed
effect.
The number of doses used for each trial is a random integer between 3 and 7
(sampled according to a uniform discrete distribution), and in all cases we have
the true MTD (whose probability of toxicity equals the target of τ = 0.33)
among the set of doses. Then, complete patients’ responses are drawn at each
dose from a Binomial distribution (1). Depending on the scenarios and on the
total number of trials used in the meta-analysis, some of the trials followed a
CRM design while others used the traditional “3+3” design(O’Quigley et al.,
1990; Le Tourneau et al., 2009). For the CRM trials, the maximum sample
size per study was sampled as an integer between 18 and 24 patients and the
number of patients at each cohort between 2 and 3 (then, the maximum number
of patients is automatically adjusted).
The (estimated) MTD is defined as the dose whose probability of toxicity is
closest to the target of τ = 0.33 and we adopted the posterior median variant
of (11) as estimation rule. The skeleton, that is the prior guesses, was chosen
to be (0.01, 0.05, 0.1, 0.15, 0.25, 0.38, 0.45), where only the probabilities linked
to the doses in the trial panel are used, and we selected the empirical working
model. Finally, the CRM trials adopted the “no skipping” rule, that is, a higher
dose is proposed to the next cohort only if all previous dose levels have already
been given, while no stopping criteria were set.
In Scenarios 1-4 the true MTD is shifted from dose level 3 to dose level
6, while keeping the same σ = 0.3. This allows us to test the impact of the
number of doses and MTD position in the meta-analysis run. Scenarios 5 and
6 have the same p? of Scenario 2, but we double the heterogeneity parameter
in Scenario 5 and we allow for dose-specific heterogeneity in Scenario 6. Then,
Scenario 7 was added to check the impact of generating data under another
Gaussian process. We evaluated the performance of the proposed model in case
of 10 trials (made by 5 CRM and 5 3+3) and 5 trials (3 CRM and 2 3+3) at
each meta-analysis run. In the last two scenarios, that is, Scenarios 8 and 9, we
evaluate the results given if all studies used an algorithm design (i.e. 3+3) or
model based design (i.e. the CRM), respectively. The simulation scenarios are
summarised in Table 3.
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Table 3: Settings and parameters in the 9 different simulation scenarios.
Scenario
Fixed effect
Random effect Studies design
true p?
1 a) OUP, σ = 0.3 CRM and 3+3
2 b) OUP, σ = 0.3 CRM and 3+3
3 c) OUP, σ = 0.3 CRM and 3+3
4 d) OUP, σ = 0.3 CRM and 3+3
5 b) OUP, σ = 0.6 CRM and 3+3
6
b) Σ =
[
exp
(
− |δi,j |l
)
σiσj
]
CRM and 3+3
and σ = (0.1, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6)
7 c) Σ =
[
exp
(
− δ
2
i,j
2l2
)
σ2m
]
, σ = 0.3 CRM and 3+3
8 c) OUP, σ = 0.3 only 3+3 design
9 c) OUP, σ = 0.3 only CRM design
4.2 Prior settings
When running a single meta-analysis, the user knows in advance the number of
doses in the analysis and it is natural to select prior distribution which suggest
the MTD in the second half part of the dose panel. However, during simulations,
depending on the scenarios, the number of doses in the panel and the related
number of increments can vary considerably. Therefore, even if it is not strictly
necessary in a single run, we used a variation of the empirical Bayes approach
to adaptively select the prior parameters of the Gamma prior process, taking
care about the number of dose increments in the actual run. Specifically, we
compute the empirical probability of toxicity of each dose by summing all DLTs
reported on all studies at the same dose level and dividing it by the total number
of patients treated at this dose level (in all studies). A linear order isotonic
regression, which uses the pool adjacent violators algorithm, was then applied
to assure the non-decreasing behaviour of the dose-toxicity curve. Finally, the
empirical MTD was selected as the dose whose empirical probability of toxicity
is closest to the target, set as 0.33 in this simulation study. The set of parameters
was chosen looking at the difference between the selected MTD and the first dose
in the panel: if the difference is less or equal to two units, we select µ∗ = −2,
σ∗ = 5, a = 0.667 and c = 0.5 which gives the induced prior probability of
toxicities shown in Figure 2; otherwise, we select µ∗ = −4, σ∗ = 3.5, a = 0.642
and c = 0.5 which gives the induced prior probability of toxicities shown in
Figure 3. These values were chosen in order to have a good trade-off between
ESS (lower numbers are desirable to have weakly informative prior) and the
prior MTD placed at second and fifth increment, respectively.
Finally, a half-Normal distribution was chosen as prior distribution for σm
and an inverse Gamma distribution with shape and scale equal to 1 for `.
The resulting model will be referred as MADF from now on.
4.3 Sensitivity analyses
We performed sensitivity analyses to check the impact of prior distributions
and/or random-effects model misspecification. We considered four model mod-
ifications, changing the prior distribution for the fixed effect, or changing the
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Figure 2: Prior distribution shown by number of dose increments.
correlation structure for the random effects (or both).
Let MADF1 denote the model MADF where (5) is substituted by
µi ∼ Gamma(k = κ, θ) i > 1,
that is, the process assumes identical dose increments and all µi>1 have the
same prior distribution. In particular, we chose κ = 3 and θ = 2 which led to
very “pessimistic” prior probabilities of toxicities, that is, the prior probabilities
of toxicities tends to be close to 1 for all doses larger than the first one.
MADF2, instead, denotes the model MADF with Σ as the variance-covariance
of a heterogeneous first order autoregressive process, that is,
Σ =

σ21 ρσ1σ2 ρ
2σ1σ3 . . . ρ
I−1σ1σI
ρσ1σ2 σ
2
2 ρσ2σ3 . . . ρ
I−2σ2σI
ρ2σ1σ3 ρσ2σ3 σ
2
3 . . . ρ
I−3σ3σI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ρI−1σ1σI . . . . . . . . . σ2I
 ,
along with a half-normal distribution with scale 1 as prior distribution for each
σi, and a uniform distribution across the interval [0, 1] for ρ.
In MADF3, Σ = σI, where II represents the identity matrix of I×I dimen-
sions. In this case, random effects are uncorrelated and each dose has a proper
scalar value. Again, σ ∼ Halfnormal(0, 1).
Finally, MADF4 shares the same model of MADF3 except for the Gamma
prior distribution, which is µ∗ = −2, σ∗ = 7, a = 3 and c = 0.5 if the increment
is less or equal to two units; otherwise, µ∗ = −4, σ∗ = 10, a = 3 and c = 2.
4.4 Results
Table 4 shows the results in terms of percentage of correct MTD selection (PCS)
of the proposed method, MADF, versus the ZKO, when 10 studies are included
in each meta-analysis run. MADF has higher PCS, ranging from 0.61 to 0.92,
while ZKO performs well in the range from 0.50 to 0.72. This could be expected,
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Figure 3: Prior distribution shown by number of dose increments.
since ZKO does not take into account heterogeneity between trials. ZKO tends
to select overdoses more often than MADF, for example in Scenario 1, where
the MTD is at dose level 3, MADF suggests 34% over toxic doses versus 41% of
ZKO. PCS percentages decrease as σ increases, as in Scenario 5, and are stable
for random-effects misspecification, as in Scenarios 6 and 7.
These percentages decrease when only 5 studies are incorporated in the meta-
analysis. The results are shown in Table 5, where MADF has still higher PCS,
ranging from 0.5 to 0.82, while ZKO has performance ranging from 0.38 to 0.61.
Figure 4 resumes the results of the sensitivity analysis in terms of percentage
of correct selection when 10 studies are adopted in each analysis. MADF1 has
the best performance in Scenarios 1 and 6, while MADF3 is the best method in
Scenario 4. MADF4 has the lowest PCS in all scenarios. Full results are given
in Table 6 in the Appendix. We can see the same trend for 5 studies, except in
Scenario 4, where MADF1 gets the lowest PCS (full results given in Table 7 in
Appendix).
5 Application to case studies
5.1 The sorafenib example
We applied the MADF method, with the same setting and prior distributions
as described in the previous section, to both examples introduced in Section 2.
Regarding the sorafenib example, Figure 5 shows the posterior distribution ob-
tained for the probability of toxicity associated to each dose panel level. Using
the posterior median variant of (11), we obtain the following estimates (0.032,
0.058, 0.085, 0.123, 0.307, 0.556, 0.834). This leads to selecting dose 600 mg as
MTD if τ = 0.33 or τ = 0.25, while 400 mg is chosen when τ = 0.20. Adopting
the EWOC rules as in (12), that is computing P
(
pii ≥ τ
∣∣ y), we obtain (0, 0,
0, 0, 0.369, 0.991, 1), (0, 0, 0, 0.002, 0.832, 1, 1) and (0, 0, 0.001, 0.016, 0.964,
1, 1) for τ = 0.33, τ = 0.25 and τ = 0.20, respectively. Setting τo = 0.25, we
select dose 400 mg in all cases.
12
Table 4: Percentage of dose selection with 10 studies for each meta-analysis
method.
Dose levels
1 2 3 4 5 6 7
Scenario 1
MADF 0.000 0.082 0.612 0.305 0.001 0.000 0.000
ZKO 0.022 0.190 0.496 0.253 0.034 0.002 0.003
#patients 31 (23, 41) 31 (23, 41) 54 (43, 65) 15 (9, 23) 6 (3, 12) 2 (0, 6) 0 (0, 3)
Scenario 2
MADF 0.000 0.000 0.032 0.920 0.048 0.000 0.000
ZKO 0.000 0.002 0.052 0.695 0.233 0.013 0.005
#patients 22 (18, 26) 26 (20, 32) 29 (23, 37) 59 (50, 68) 14 (9, 20) 5 (0, 9) 0 (0, 3)
Scenario 3
MADF 0.000 0.000 0.000 0.084 0.834 0.082 0.000
ZKO 0.000 0.000 0.002 0.075 0.676 0.216 0.031
#patients 22 (17, 26) 23 (19, 29) 26 (20, 33) 29 (22, 38) 45 (36, 54) 11.5 (6, 18) 6 (2, 12)
Scenario 4
MADF 0.000 0.000 0.000 0.000 0.228 0.758 0.014
ZKO 0.000 0.000 0.000 0.001 0.131 0.680 0.188
#patients 43 (37, 51) 43 (37, 51) 24 (19, 31) 26 (20, 34) 26 (20, 33) 40 (32, 48) 11 (6, 18)
Scenario 5
MADF 0.000 0.000 0.085 0.781 0.134 0.000 0.000
ZKO 0.004 0.037 0.162 0.561 0.215 0.017 0.004
#patients 24 (19, 31) 27 (20, 35) 28 (21, 37) 51 (41, 59) 13 (8, 20) 6 (2, 12) 0 (0, 6)
Scenario 6
MADF 0.000 0.000 0.019 0.882 0.099 0.000 0.000
ZKO 0.000 0.000 0.022 0.665 0.287 0.015 0.011
#patients 21 (17, 26) 25 (20, 30) 30 (23, 37) 61 (53, 69) 14 (8, 20) 5 (0, 9) 0 (0, 4)
Scenario 7
MADF 0.000 0.000 0.000 0.069 0.830 0.101 0.000
ZKO 0.000 0.000 0.002 0.075 0.653 0.245 0.025
#patients 22 (18, 26) 22.5 (18, 28) 27 (20, 33.25) 30 (23, 38) 45 (36, 54) 12 (6, 18) 6 (3, 12)
Scenario 8
MADF 0.000 0.000 0.000 0.150 0.773 0.077 0.000
ZKO 0.000 0.000 0.002 0.078 0.591 0.295 0.034
#patients 24 (18, 27) 24 (18, 27) 24 (18, 27) 24 (18, 27) 30 (24, 36) 9 (3, 12) 3 (0, 6)
Scenario 9
MADF 0.000 0.000 0.000 0.064 0.837 0.099 0.000
ZKO 0.000 0.000 0.001 0.076 0.715 0.194 0.014
#patients 20 (16, 25) 24 (18, 31) 30 (23, 39) 37 (27, 47) 60 (49, 71) 15 (9, 23) 10 (4, 16)
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Table 5: Percentage of dose selection with 5 studies for each meta-analysis
method.
Dose levels
1 2 3 4 5 6 7
Scenario 1
MADF 0.007 0.153 0.498 0.324 0.018 0.000 0.000
ZKO 0.032 0.177 0.377 0.292 0.089 0.026 0.007
#patients 15 (10, 23) 16 (10, 23) 29 (21, 37) 8 (3, 14) 3 (0, 6) 0 (0, 3) 0 (0, 0)
Scenario 2
MADF 0.000 0.002 0.068 0.826 0.103 0.001 0.000
ZKO 0.005 0.007 0.060 0.490 0.367 0.055 0.016
#patients 11 (8, 14) 12 (9, 17) 15 (9, 21) 32 (26, 38) 6 (3, 12) 0 (0, 6) 0 (0, 0)
Scenario 3
MADF 0.000 0.000 0.003 0.169 0.683 0.144 0.001
ZKO 0.000 0.000 0.013 0.133 0.544 0.261 0.049
#patients 11 (8, 14) 11 (8, 15) 13 (9, 18) 15 (9, 21) 24 (18, 30) 6 (2, 10) 2 (0, 6)
Scenario 4
MADF 0.000 0.000 0.000 0.003 0.320 0.622 0.055
ZKO 0.000 0.000 0.001 0.013 0.179 0.610 0.197
#patients 21 (17, 26) 21 (17, 26) 12 (8, 16) 12 (8, 18) 12.5 (9, 18) 20 (14, 27) 6 (0, 11)
Scenario 5
MADF 0.000 0.017 0.153 0.622 0.200 0.008 0.000
ZKO 0.015 0.045 0.117 0.436 0.299 0.076 0.012
#patients 11 (8, 16) 13 (9, 19) 14 (9, 20) 27 (20, 34) 6 (3, 12) 3 (0, 6) 0 (0, 3)
Scenario 6
MADF 0.000 0.000 0.059 0.802 0.137 0.002 0.000
ZKO 0.000 0.002 0.04 0.449 0.412 0.065 0.032
#patients 11 (8, 14) 12 (9, 16) 15 (10, 21) 33 (27, 39) 6 (3, 12) 2 (0, 6) 0 (0, 2)
Scenario 7
MADF 0.000 0.000 0.001 0.152 0.692 0.155 0.000
ZKO 0.001 0.000 0.007 0.106 0.546 0.271 0.069
#patients 11 (8, 14) 11 (8, 15) 13 (9, 18) 15 (9, 21) 24 (17, 30) 6 (2, 11) 3 (0, 6)
Scenario 8
MADF 0.000 0.001 0.009 0.203 0.668 0.116 0.003
ZKO 0.000 0.001 0.017 0.134 0.489 0.282 0.077
#patients 12 (9, 15) 12 (9, 15) 12 (9, 15) 12 (9, 15) 15 (12, 18) 3 (0, 6) 0 (0, 3)
Scenario 9
MADF 0.000 0.000 0.002 0.143 0.713 0.141 0.001
ZKO 0.000 0.000 0.005 0.125 0.557 0.269 0.044
#patients 10 (7, 13) 11 (8, 16) 14 (9, 21) 18 (11.75, 25) 30 (22, 38) 7 (2, 13) 3 (0, 10)
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Figure 4: Results in terms of percentage of correct selection when 10 studies
are adopted in each analysis. In each scenario, the name of the method with
the high percentage of correct selection is shown.
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Figure 5: Posterior distributions for dose-limiting toxicity probability each dose
level for the sorafenib example.
Figure 6: Posterior distributions for dose-limiting toxicity probability at each
dose level for the irinotecan + S-1 example.
5.2 The irinotecan / S-1 example
Results of the irinotecan + S-1 example are shown in Figure 6. Differently from
before, here δ∗i,j =
di−dj
10mgm−2 , while δ has the same specification as before. Again,
using the posterior median variant of (11), we obtain the following estimates
(0.022, 0.039, 0.070, 0.114, 0.194, 0.292, 0.413, 0.625, 0.678, 0.884). This leads
to selecting dose 90 mg/m2 as MTD if τ = 0.33 or τ = 0.25, while 80 mg/m2 is
chosen when τ = 0.20. Adopting the EWOC rules as in (12), we obtain (0, 0,
0, 0.004, 0.061, 0.349, 0.773, 0.990, 0.996, 1), (0, 0, 0.002, 0.027, 0.238, 0.677,
0.944, 0.998, 1, 1) and (0, 0.001, 0.008, 0.082, 0.466, 0.866, 0.984, 1, 1, 1) for
τ = 0.33, τ = 0.25 and τ = 0.20, respectively. Setting τo = 0.25, we select dose
80 mg/m2 in the first two cases and 70 mg/m2 in the last one.
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6 Discussion
We proposed a new methodology for random-effects meta-analysis of phase I
dose-finding trials, based on a Gaussian process for the random effect structure,
and a Gamma process as a prior distribution for the fixed effects. The Gaussian
process permits to share more information when doses are closer and less infor-
mation when they are distant. In this way, for example, regarding a dose panel,
dose level 3 and 4 are more correlated than dose level 1 and 4. And the amount
of correlation depends on the distance, that seems more logical than assuming
a constant value for the correlation. The Gamma prior process preserves the
monotonicity assumption of toxicity. We do not suggest to add the full process
to be estimated, since, in our experience, even if in meta-analysis more data are
available than a single dose-finding trial, data are still not sufficient for a good
estimation of the process parameters (results not shown in the paper). To note,
we focused on modelling toxicities exactly at the doses di that had also been
investigated in the analysed trials. In general, in case of rich data and when the
estimation of the underlying Gamma process is feasible, the full model actually
also allows to interpolate or extrapolate across the continuum of doses. In this
case, guidance on how to set the prior distributions can be found in Gelman
et al. (2008).
Since the two metrics used in the fixed effect prior and random effect, that
is δ∗ and δ, respectively, are linked to each others via linear transformation,
one can also consider to use the same metric and scaling the prior distributions
accordingly.
With the above model specifications, we have generalized the BNHM, as an
obvious approach for the single-dose case, to the case of several adjacent doses.
Note that for the special case of a single dose, we actually again recover the
BNHM with the parameters µ1 and σm corresponding to the overall mean and
heterogeneity parameters.
In our results, ZKO had lower PCS performance. This is expected, since this
method does not take into account the heterogeneity between trials. Also as
expected, PCSs decrease when heterogeneity increases and when only 3+3 dose-
finding trials are incorporated in meta-analysis (scenario 5 and 8, respectively).
MADF showed to be stable to models misspecification, as we can see in the
results of scenario 6 and 7 compared to scenario 2 and 3, respectively. On the
other hand, prior specification and simpler models, as MADF3 and MADF4 can
give different operating characteristic. A conservative Gamma process prior, as
MADF1, has better PCS when the MTD is located at the beginning of the dose
panel. Actually, this situation is not very realistic, since it would imply that
really few safe doses where repeatedly tested in several clinical trials.
Appendix
Sensitivity analysis tables
Tables 6 and 7 show the full results, in terms of percentage of MTD selection,
of the sensitivity analysis performed.
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Table 6: Sensitivity analysis results: percentage of correct selection with 10
studies for each meta-analysis method.
Dose levels
1 2 3 4 5 6 7
Scenario 1
MADF1 0.000 0.118 0.804 0.078 0.000 0.000 0.000
MADF2 0.000 0.071 0.690 0.232 0.007 0.000 0.000
MADF3 0.000 0.049 0.508 0.422 0.021 0.000 0.000
MADF4 0.000 0.045 0.456 0.406 0.088 0.004 0.001
Scenario 2
MADF1 0.000 0.000 0.079 0.908 0.013 0.000 0.000
MADF2 0.000 0.000 0.043 0.897 0.060 0.000 0.000
MADF3 0.000 0.000 0.017 0.882 0.101 0.000 0.000
MADF4 0.000 0.000 0.026 0.840 0.131 0.003 0.000
Scenario 3
MADF1 0.000 0.000 0.000 0.229 0.735 0.036 0.000
MADF2 0.000 0.000 0.000 0.101 0.709 0.185 0.005
MADF3 0.000 0.000 0.000 0.056 0.773 0.171 0.000
MADF4 0.000 0.000 0.000 0.061 0.554 0.329 0.056
Scenario 4
MADF1 0.000 0.000 0.000 0.002 0.354 0.638 0.006
MADF2 0.000 0.000 0.000 0.000 0.132 0.758 0.110
MADF3 0.000 0.000 0.000 0.000 0.139 0.819 0.042
MADF4 0.000 0.000 0.000 0.000 0.078 0.585 0.337
Scenario 5
MADF1 0.000 0.001 0.216 0.747 0.036 0.000 0.000
MADF2 0.000 0.001 0.105 0.734 0.156 0.004 0.000
MADF3 0.000 0.000 0.043 0.653 0.303 0.001 0.000
MADF4 0.000 0.000 0.051 0.575 0.337 0.037 0.000
Scenario 6
MADF1 0.000 0.000 0.053 0.918 0.029 0.000 0.000
MADF2 0.000 0.000 0.028 0.892 0.080 0.000 0.000
MADF3 0.000 0.000 0.009 0.820 0.171 0.000 0.000
MADF4 0.000 0.000 0.022 0.798 0.172 0.008 0.000
Scenario 7
MADF1 0.000 0.000 0.000 0.208 0.751 0.041 0.000
MADF2 0.000 0.000 0.001 0.088 0.696 0.210 0.005
MADF3 0.000 0.000 0.000 0.049 0.753 0.198 0.000
MADF4 0.000 0.000 0.000 0.050 0.534 0.349 0.067
Scenario 8
MADF1 0.000 0.000 0.003 0.338 0.630 0.029 0.000
MADF2 0.000 0.000 0.002 0.149 0.647 0.192 0.010
MADF3 0.000 0.000 0.000 0.085 0.730 0.185 0.000
MADF4 0.000 0.000 0.001 0.077 0.511 0.339 0.072
Scenario 9
MADF1 0.000 0.000 0.001 0.167 0.773 0.059 0.000
MADF2 0.000 0.000 0.000 0.091 0.699 0.205 0.005
MADF3 0.000 0.000 0.000 0.044 0.771 0.185 0.000
MADF4 0.000 0.000 0.000 0.048 0.578 0.331 0.043
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Table 7: Sensitivity analysis results: percentage of correct selection with 5
studies for each meta-analysis method.
Dose levels
1 2 3 4 5 6 7
Scenario 1
MADF1 0.004 0.213 0.637 0.138 0.008 0.000 0.000
MADF2 0.005 0.142 0.585 0.235 0.030 0.003 0.000
MADF3 0.007 0.117 0.463 0.361 0.051 0.001 0.000
MADF4 0.003 0.112 0.457 0.317 0.093 0.017 0.001
Scenario 2
MADF1 0.000 0.002 0.163 0.796 0.038 0.001 0.000
MADF2 0.000 0.002 0.095 0.817 0.084 0.002 0.000
MADF3 0.000 0.000 0.046 0.801 0.152 0.001 0.000
MADF4 0.000 0.000 0.058 0.766 0.170 0.005 0.001
Scenario 3
MADF1 0.000 0.000 0.011 0.333 0.588 0.068 0.000
MADF2 0.000 0.000 0.003 0.206 0.599 0.178 0.014
MADF3 0.000 0.000 0.001 0.132 0.659 0.205 0.003
MADF4 0.000 0.000 0.001 0.116 0.555 0.253 0.075
Scenario 4
MADF1 0.000 0.000 0.001 0.034 0.456 0.488 0.021
MADF2 0.000 0.000 0.000 0.010 0.250 0.634 0.106
MADF3 0.000 0.000 0.000 0.001 0.246 0.673 0.080
MADF4 0.000 0.000 0.000 0.002 0.151 0.568 0.279
Scenario 5
MADF1 0.000 0.019 0.284 0.614 0.079 0.004 0.000
MADF2 0.000 0.015 0.187 0.589 0.191 0.016 0.002
MADF3 0.000 0.011 0.097 0.578 0.301 0.013 0.000
MADF4 0.000 0.009 0.104 0.531 0.286 0.065 0.005
Scenario 6
MADF1 0.000 0.000 0.129 0.812 0.057 0.002 0.000
MADF2 0.000 0.000 0.082 0.802 0.111 0.005 0.000
MADF3 0.000 0.000 0.045 0.769 0.179 0.007 0.000
MADF4 0.000 0.000 0.053 0.731 0.186 0.028 0.002
Scenario 7
MADF1 0.000 0.000 0.013 0.317 0.600 0.070 0.000
MADF2 0.000 0.000 0.004 0.170 0.610 0.202 0.014
MADF3 0.000 0.000 0.001 0.123 0.658 0.214 0.004
MADF4 0.000 0.000 0.002 0.104 0.516 0.290 0.088
Scenario 8
MADF1 0.000 0.000 0.042 0.413 0.500 0.044 0.001
MADF2 0.000 0.000 0.015 0.232 0.554 0.181 0.018
MADF3 0.000 0.001 0.005 0.150 0.645 0.192 0.007
MADF4 0.000 0.000 0.005 0.141 0.514 0.248 0.092
Scenario 9
MADF1 0.000 0.000 0.008 0.271 0.635 0.085 0.001
MADF2 0.000 0.000 0.005 0.173 0.622 0.189 0.011
MADF3 0.000 0.000 0.002 0.114 0.684 0.196 0.004
MADF4 0.000 0.000 0.005 0.095 0.552 0.279 0.069
19
References
A. Awada, A. Hendlisz, T. Gil, S. Bartholomeus, M. Mano, D. De Valeriola,
D. Strumberg, E. Brendel, C. G. Haase, B. Schwartz, et al. Phase I safety
and pharmacokinetics of BAY 43-9006 administered for 21 days on / 7 days
off in patients with advanced, refractory solid tumours. British Journal of
Cancer, 92(10):1855, 2005.
J. Babb, A. Rogatko, and S. Zacks. Cancer phase I clinical trials: efficient dose
escalation with overdose control. Statistics in Medicine, 17(10):1103–1120,
1998.
G. Borthakur, H. Kantarjian, F. Ravandi, W. Zhang, M. Konopleva, J. J.
Wright, S. Faderl, S. Verstovsek, S. Mathews, M. Andreeff, et al. Phase I
study of sorafenib in patients with refractory or relapsed acute leukemias.
Haematologica, 96(1):62–68, 2011.
F. Bretz, J. C. Pinheiro, and M. Branson. Combining multiple comparisons
and modeling techniques in dose-response studies. Biometrics, 61(3):738–748,
2005.
Y.-B. Chen, S. Li, A. A. Lane, C. Connolly, C. Del Rio, B. Valles, M. Curtis,
K. Ballen, C. Cutler, B. R. Dey, et al. Phase I trial of maintenance sorafenib
after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine
kinase 3 internal tandem duplication acute myeloid leukemia. Biology of Blood
and Marrow Transplantation, 20(12):2042–2048, 2014.
Y. K. Cheung. Dose finding by the continual reassessment method. Chapman
and Hall/CRC, 2011.
S. Chevret. Statistical methods for dose-finding experiments of Statistics in
practice. John Wiley and Sons, Chichester, West Sussex, England, 2006.
J. W. Clark, J. P. Eder, D. Ryan, C. Lathia, and H.-J. Lenz. Safety and phar-
macokinetics of the dual action Raf kinase and vascular endothelial growth
factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory
solid tumors. Clinical Cancer Research, 11(15):5472–5480, 2005.
M. Crump, D. Hedley, S. Kamel-Reid, B. Leber, R. Wells, J. Brandwein,
R. Buckstein, J. Kassis, M. Minden, J. Matthews, et al. A randomized
phase I clinical and biologic study of two schedules of sorafenib in patients
with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (Na-
tional Cancer Institute of Canada) clinical trials group study. Leukemia &
Lymphoma, 51(2):252–260, 2010.
J. L. Doob. The Brownian movement and stochastic equations. Annals of
Mathematics, 42:351–369, 1942.
T. Friede, C. Ro¨ver, S. Wandel, and B. Neuenschwander. Meta-analysis of few
small studies in orphan diseases. Research Synthesis Methods, 8(1):79–91,
2017.
J. Furuse, H. Ishii, K. Nakachi, E. Suzuki, S. Shimizu, and K. Nakajima. Phase I
study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer
Science, 99(1):159–165, 2008.
20
A. Gelman, A. Jakulin, M. G. Pittau, and Y.-S. Su. A weakly informative
default prior distribution for logistic and other regression models. The Annals
of Applied Statistics, 2(4):1360–1383, Dec. 2008. doi: 10.1214/08-AOAS191.
A. Gelman, J. B. Carlin, H. Stern, D. B. Dunson, A. Vehtari, and D. B. Rubin.
Bayesian data analysis. Chapman & Hall / CRC, Boca Raton, 3rd edition,
2014.
H. Goya, H. Kuraishi, S. Koyama, T. Ichiyama, F. Yoshiike, K. Hirai, T. Agat-
suma, K. Tateishi, S. Kanda, H. Yamamoto, et al. Phase I/II study of S-1
combined with biweekly irinotecan chemotherapy in previously treated ad-
vanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology,
70(5):691–697, 2012.
B. K. Gu¨nhan, S. Ro¨ver, and T. Friede. Meta-analysis of few studies involving
rare events. Research Synthesis Methods, in press, 2019. doi: 10.1002/jrsm.
1370.
M. Inokuchi, T. Yamashita, H. Yamada, K. Kojima, W. Ichikawa, Z. Nihei,
T. Kawano, and K. Sugihara. Phase I/II study of S-1 combined with irinote-
can for metastatic advanced gastric cancer. British Journal of Cancer, 94(8):
1130, 2006.
O. Ishimoto, T. Ishida, Y. Honda, M. Munakata, and S. Sugawara. Phase I
study of daily S-1 combined with weekly irinotecan in patients with advanced
non-small cell lung cancer. International Journal of Clinical Oncology, 14(1):
43–47, 2009.
D. Jackson, M. Law, T. Stijnen, W. Viechtbauer, and I. R. White. A comparison
of seven random-effects models for meta-analyses that estimate the summary
odds ratio. Statistics in Medicine, 37(7):1059–1085, Mar. 2018. doi: 10.1002/
sim.7588.
N. Jia, I. Liou, J. Halldorson, R. Carithers, J. Perkins, J. Reyes, M. Yeh,
E. Stohr, S. Rao, and E. H. Lin. Phase I adjuvant trial of sorafenib in pa-
tients with hepatocellular carcinoma after orthotopic liver transplantation.
Anticancer Research, 33(6):2797–2800, 2013.
Y. Komatsu, S. Yuki, N. Fuse, T. Kato, T. Miyagishima, M. Kudo, Y. Kunieda,
M. Tateyama, O. Wakahama, T. Meguro, et al. Phase 1/2 clinical study
of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Advances in Therapy, 27(7):483–492, 2010.
H. Kusaba, T. Esaki, K. Futami, S. Tanaka, H. Fujishima, K. Mitsugi, K. Sakai,
H. Ariyama, R. Tanaka, N. Kinugawa, et al. Phase I/II study of a 3-week
cycle of irinotecan and S-1 in patients with advanced colorectal cancer. Cancer
Science, 101(12):2591–2595, 2010.
J. Lawless and M. Crowder. Covariates and random effects in a gamma process
model with application to degradation and failure. Lifetime Data Analysis,
10(3):213–227, 2004.
21
C. Le Tourneau, J. J. Lee, and L. L. Siu. Dose escalation methods in phase I
cancer clinical trials. Journal of the National Cancer Institute, 101(10):708–
720, 2009.
A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, E. B. Kennedy, G. Abou-Alfa,
A. Desai, J. Hwang, M. A. Villalona-Calero, E. C. Dees, et al. Phase I and
pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunc-
tion: CALGB 60301. Journal of Clinical Oncology, 27(11):1800, 2009.
H. Minami, K. Kawada, H. Ebi, K. Kitagawa, Y.-i. Kim, K. Araki, H. Mukai,
M. Tahara, H. Nakajima, and K. Nakajima. Phase I and pharmacokinetic
study of sorafenib, an oral multikinase inhibitor, in Japanese patients with
advanced refractory solid tumors. Cancer Science, 99(7):1492–1498, 2008.
M. Moore, H. Hirte, L. Siu, A. Oza, S. Hotte, O. Petrenciuc, F. Cihon, C. Lathia,
and B. Schwartz. Phase I study to determine the safety and pharmacokinetics
of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for
28 days on / 7 days off in patients with advanced, refractory solid tumors.
Annals of Oncology, 16(10):1688–1694, 2005.
S. Morita, P. Thall, and P. Mu¨ller. Determining the effective sample size of
a parametric prior. Biometrics, 64(2):595–602, June 2008. doi: 10.1111/j.
1541-0420.2007.00888.x.
L. Nabors, J. Supko, M. Rosenfeld, M. Chamberlain, S. Phuphanich, T. Batch-
elor, S. Desideri, X. Ye, J. Wright, S. Gujar, et al. Phase I trial of sorafenib
in patients with recurrent or progressive malignant glioma. Neuro-Oncology,
13(12):1324–1330, 2011.
Y. Nakafusa, M. Tanaka, T. Ohtsuka, A. Miyoshi, N. Kohya, Y. Kitajima,
S. Sato, S. Mochinaga, S. Dohi, and K. Miyazaki. Phase I/II study of combi-
nation therapy with s-1 and cpt-11 for metastatic colorectal cancer. Molecular
Medicine Reports, 1(6):925–930, 2008.
B. Neuenschwander, M. Branson, and T. Gsponer. Critical aspects of the
Bayesian approach to phase I cancer trials. Statistics in Medicine, 27(13):
2420–2439, June 2008. doi: 10.1002/sim.3230.
B. Neuenschwander, A. Matano, Z. Tang, S. Roychoudhury, S. Wandel, and
S. Bailey. A Bayesian industry approach to phase I combination trials in
oncology. In W. Zhao and H. Yang, editors, Statistical methods in drug com-
bination studies, chapter 6, pages 95–135. Chapman & Hall / CRC, Boca
Raton, 2015.
Y. Ogata, T. Sasatomi, Y. Akagi, N. Ishibashi, S. Mori, and K. Shirouzu. Dosage
escalation study of S-1 and irinotecan in metronomic chemotherapy against
advanced colorectal cancer. The Kurume Medical Journal, 56(1+ 2):1–7, 2009.
J. O’Quigley and S. Zohar. Retrospective robustness of the continual reassess-
ment method. J Biopharm Stat, 20(5):1013–1025, Sep 2010.
J. O’Quigley, M. Pepe, and L. Fisher. Continual reassessment method: a prac-
tical design for phase 1 clinical trials in cancer. Biometrics, pages 33–48,
1990.
22
T. L. Schwinghammer and P. D. Kroboth. Basic concepts in pharmacodynamic
modeling. Journal of Clinical Pharmacology, 28(5):388–394, May 1988. doi:
10.1002/j.1552-4604.1988.tb05745.x.
M. Shiozawa, N. Sugano, K. Tsuchida, S. Morinaga, M. Akaike, and Y. Sugi-
masa. A phase I study of combination therapy with S-1 and irinotecan (CPT-
11) in patients with advanced colorectal cancer. Journal of Cancer Research
and Clinical Oncology, 135(3):365–370, 2009.
F. W. Steutel. Infinite divisibilty in theory and practice. Scandinavian Journal
of Statistics, 6(2):57–64, 1979.
D. Strumberg, H. Richly, R. A. Hilger, N. Schleucher, S. Korfee, M. Tewes,
M. Faghih, E. Brendel, D. Voliotis, C. G. Haase, et al. Phase I clinical and
pharmacokinetic study of the novel Raf kinase and vascular endothelial growth
factor receptor inhibitor BAY 43-9006 in patients with advanced refractory
solid tumors. Journal of Clinical Oncology, 23(5):965–972, 2005.
H. Takiuchi, H. Narahara, T. Tsujinaka, M. Gotoh, S.-i. Kawabe, K.-i. Katsu,
H. Iishi, M. Tatsuta, K. Fujitani, H. Furukawa, et al. Phase I study of S-1
combined with irinotecan (CPT-11) in patients with advanced gastric cancer
(OGSG 0002). Japanese Journal of Clinical Oncology, 35(9):520–525, 2005.
N. Thomas, K. Sweeney, and V. Somayaji. Meta-analysis of clinical dose-
response in a large drug development portfolio. Statistics in Biopharma-
ceutical Research, 6(4):302–317, 2014.
R. M. Turner, J. Davey, M. J. Clarke, S. G. Thompson, and J. P. T. Higgins.
Predicting the extent of heterogeneity in meta-analysis, using empirical data
from the Cochrane Database of Systematic Reviews. International Journal
of Epidemiology, 41(3):818–827, June 2012. doi: 10.1093/ije/dys041.
G. E. Uhlenbeck and L. S. Ornstein. On the theory of Brownian motion. Physical
Review, 36(5):823–841, Sept. 1930. doi: 10.1103/PhysRev.36.823.
M. Ursino, Y. Yuan, C. Alberti, E. Comets, G. Favrais, T. Friede, F. Lentz,
N. Stallard, and S. Zohar. A dose finding design for seizure reduction in
neonates. Journal of the Royal Statistical Society: Series C (Applied Statis-
tics), 68(2):427–444, 2019.
S. Yoda, K. Soejima, H. Yasuda, K. Naoki, I. Kawada, H. Watanabe, I. Nakachi,
R. Satomi, S. Nakayama, S. Ikemura, et al. A phase I study of S-1 and
irinotecan combination therapy in previously treated advanced non-small cell
lung cancer patients. Cancer Chemotherapy and Pharmacology, 67(3):717–
722, 2011.
S. Zohar, S. Katsahian, and J. O’Quigley. An approach to meta-analysis of
dose-finding studies. Statistics in Medicine, 30(17):2109–2116, 2011. doi:
10.1002/sim.4121.
23
